Advanced search×

Systemic monoclonal antibody therapy (daclizumab) in the treatment of cicatrizing conjunctivitis in stevens-johnson syndrome, refractory to conventional therapy.

Curr Eye Res 35(12):1057-62 (2010) PMID 20929291

At least one-year follow-up of a case series of young Stevens-Johnson syndrome (SJS) patients with cicatrizing ocular surface disease and recurrent inflammation (SJS-RI) treated with systemic humanized monoclonal antibody (daclizumab).

DOI: 10.3109/02713683.2010.511392
Version: za2963e q8za1 q8zb7 q8zc7 q8zdf q8ze0 q8zf1 q8zgd

Similar articles you may find interesting…

  1. Synergistic effect of platelet-activating factor and tumor necrosis factor-alpha on corneal myofibroblast apoptosis.

    Invest Ophthalmol Vis Sci 47(3):883-91 (2006) PMID 16505020

    Corneal myofibroblasts express a PAF receptor in the nuclear membrane, and they also express TNF-RI and RII. The synergistic effect on myofibroblast apoptosis by PAF and TNF-alpha suggests that during corneal stromal wound healing, PAF acting in conjunction with other cytokines could play an importa...
  2. Mapping the entire human corneal nerve architecture

    Exp Eye Res 91(4):11 (2010) PMID 20650270 PMCID PMC2939211

    We developed an approach to generate a three-dimensional map that facilitates the assessment of epithelial nerve density in different corneal areas to define aging and gender influence on human corneal nerve architecture. Twenty-eight fresh human eyes from 14 donors of different ages were studied. C...
  3. PAF-induced furin and MT1-MMP expression is independent of MMP-2 activation in corneal myofibroblasts.

    Invest Ophthalmol Vis Sci 46(2):487-96 (2005) PMID 15671273

    PAF, through a receptor-mediated mechanism, induces a specific pattern of furin, MMP, and TIMP-2 expression in corneal myofibroblasts. MMP-2 activity was unchanged by PAF treatment. These results suggest that in response to the inflammatory mediator PAF, induction of MT1-MMP is independent of MMP-2...